GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Liabilities-to-Assets

Ablynx NV (XBRU:ABLXS) Liabilities-to-Assets : 0.54 (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Ablynx NV's Total Liabilities for the quarter that ended in Dec. 2017 was €209.99 Mil. Ablynx NV's Total Assets for the quarter that ended in Dec. 2017 was €389.85 Mil. Therefore, Ablynx NV's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2017 was 0.54.


Ablynx NV Liabilities-to-Assets Historical Data

The historical data trend for Ablynx NV's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Liabilities-to-Assets Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.66 0.90 0.61 0.54

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.60 0.61 0.66 0.54

Competitive Comparison of Ablynx NV's Liabilities-to-Assets

For the Biotechnology subindustry, Ablynx NV's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Liabilities-to-Assets falls into.



Ablynx NV Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Ablynx NV's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2017 is calculated as:

Liabilities-to-Assets (A: Dec. 2017 )=Total Liabilities/Total Assets
=209.992/389.848
=0.54

Ablynx NV's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2017 is calculated as

Liabilities-to-Assets (Q: Dec. 2017 )=Total Liabilities/Total Assets
=209.992/389.848
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Ablynx NV Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines